Europe Biosimilar Market Outlook
Base Year: 2024
Historical Years: 2019-2024
Forecast Years: 2025-2033
Industry Size in 2024: USD 13,864 Million
Forecast of Market in 2033: USD 59,733.3 Million
Market Growth Rate: 17.1% (2025-2033)
The biosimilar market in Europe was valued at USD 13,864 Million in 2024 and is projected to grow to USD 59,733.3 Million by 2033, with an expected compound annual growth rate (CAGR) of 17.1% from 2025 to 2033.
For an in-depth analysis, you can refer free sample copy of the report: https://www.imarcgroup.com/europe-biosimilar-market/requestsample
Europe Biosimilar Market Trends:
The European market base its main growth on patient demand for economical treatment solutions which specifically benefits individuals with persistent medical conditions. The market growth benefits from rising numbers of biologic drugs approaching their patent expiration timelines which provide more opportunities for biosimilars to enter the market. The expanding healthcare facilities across eastern European markets allow wider biosimilar use while regulatory practices support their adoption.
The rising healthcare costs in Europe give healthcare providers and patients grounds to consider biosimilar treatments as suitable alternatives. The market continues to grow because biosimilars deliver substantial cost savings which do not affect treatment effectiveness while reducing healthcare expenses. The market expansion receives substantial support from government bodies together with health organizations that promote biosimilar development. Healthcare professionals and patients adopt biosimilars because of expanding awareness initiatives which showcase both safety and effectiveness in treatments. Pharmaceutical companies continue to invest heavily in biosimilar research and development as a market growth driver and to establish innovation when competing against each other.
Europe Biosimilar Market Scope and Growth Analysis:
The scope of the market expands because therapeutic applications of biosimilars extend into three main areas: oncology, immunology, and endocrinology to serve unmet clinical needs. The mainstream treatment protocols incorporate biosimilars due to hospital settings adopting these products which strengthens market position. European countries with emerging markets now receive better access to advanced treatments because biosimilar drugs have become more accessible and affordable. Market efficiencies improve because of productive interactions between pharmaceutical entities and regulatory bodies that speed up the product launch process.
Local manufacturers continue to rise throughout the market which leads to product diversification specifically targeting regional consumer needs. The deployment of updated manufacturing technologies creates more production efficiency while lowering expenses and bolstering supply chain operations. The market acceptance grows because prescribers feel more confident about biosimilar interchangeability. Analytical research demonstrates that reimbursement system changes which back the acceptance of biosimilars create a favorable business context for both healthcare systems and industry stakeholders.
Ask Analyst For Customization: https://www.imarcgroup.com/request?type=report&id=1023&flag=C
By the IMARC Group, the Top Competitive Landscapes Operating in the Industry:
- Novartis
- Pfizer
- TevaÂ
- CelltrionÂ
- Merck Sharp & Dohme
- Samsung BioepisÂ
- Eli Lilly
- Accord Healthcare Ltd.
- Amgen
- Boehringer Ingelheim
- Hexal AgÂ
- ApotexÂ
- Stada Arzneimittel Ag
- Ratiopharm
- Mylan
Europe Biosimilar Industry Segmentation:
The market report offers a comprehensive analysis of the segments, highlighting those with the largest Europe biosimilar market share. It includes forecasts for the period 2025-2033 and historical data from 2019-2024 for the following segments.
Molecule Insights:
- Infliximab
- Insulin Glargine
- Epoetin Alfa
- Etanercept
- Filgrastim
- Somatropin
- Rituximab
- Follitropin Alfa
- Adalimumab
Indication Insights:
- Auto-Immune Diseases
- Blood Disorder
- Diabetes
- Oncology
- Growth Deficiency
- Female Infertility
Breakup by Manufacturing Type:
- In-house Manufacturing
- Contract Manufacturing
Breakup by Country:
- Italy
- Germany
- United Kingdom
- France
- Spain
- Rest of Europe
Key highlights of the Report:
- Market Performance (2019-2024)
- Market Outlook (2025-2033)
- COVID-19 Impact on the Market
- Porter’s Five Forces Analysis
- Strategic Recommendations
- Historical, Current and Future Market Trends
- Market Drivers and Success Factors
- SWOT Analysis
- Structure of the Market
- Value Chain Analysis
- Comprehensive Mapping of the Competitive Landscape
Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.
About Us:
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services.
IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145
